Four or five years ago I was saying, What are we doing? he notes
Given the variability in patient susceptibility, an individualized approach may be required
it plays a key role in transporting long-chain fatty acids into mitochondria for energy production
Approved for diabetes as Mounjaro in 2022 and for weight loss as Zepbound in 2023, tirzepatide has quickly become a primary option for people seeking significant weight loss

Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program, Diabetes Care (2022) What causes obesity & overweight?, Eunice Kennedy Shriver National Institute of Child Health and Human Development (2021) Compounding and the FDA: Questions and Answers, Food and Drug Administration (2024) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders (2022) FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Thinking of using a compounding pharmacy
I will keep tracking the FDA decision and any proper human trials